← Leaderboards
Min Shen
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsEnzymesMalignant NeoplasmsPharmaceutical PreparationsPharmaceutical ChemistryLeadSmall MoleculeInhibitor/AntagonistBaseInterestMetabolicCollaborationsNovel TherapeuticsSignal TransductionScreeningHigh Throughput ScreeningCessation Of LifeGrowthDrug DiscoverySmall Molecule InhibitorSymptomsCell LineAntineoplastic AgentsClassical Galactosemia
Grant awards (38)
Cytotoxicity profiling of Genesis library in A673 and Jurkat cells$278,962
ZIA · FY2025 · TR · contact PI
qHTS to Identify Inhibitors of Acral melanoma$278,962
ZIA · FY2025 · TR · contact PI
Identification of small molecules against lenvatinib-resistant thyroid cancer cells$139,481
ZIA · FY2025 · TR · contact PI
qHTS to Identify Substrates of P-glycoprotein (P-gp) and Collateral Sensitivity agents of P-gp-expressing Cancer Cells$139,481
ZIA · FY2025 · TR · contact PI
Cytotoxicity profiling of Genesis library in A673 and Jurkat cells$327,632
ZIA · FY2024 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$245,724
ZIA · FY2024 · TR · contact PI
qHTS to Identify Inhibitors of NNMT1$245,724
ZIA · FY2024 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$310,142
ZIA · FY2023 · TR · contact PI
Cytotoxicity profiling of Genesis library in A673 and Jurkat cells$125,849
ZIA · FY2023 · TR · contact PI
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia$425,400
ZIA · FY2022 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$425,400
ZIA · FY2022 · TR · contact PI
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia$350,724
ZIA · FY2021 · TR · contact PI
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia$305,662
ZIA · FY2020 · TR · contact PI
NPC/MIPE Toxicity Screen of IDH1 Inhibitors against Cholangiocarcinoma Cell Lines$305,662
ZIA · FY2020 · TR · contact PI
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia$250,290
ZIA · FY2019 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$250,290
ZIA · FY2019 · TR · contact PI
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia$245,080
ZIA · FY2018 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$245,080
ZIA · FY2018 · TR · contact PI
Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia$251,630
ZIA · FY2017 · TR · contact PI
Identification of Inhibitors of the Lipid Kinase PI5P4Ka/B as Potential Anti-Cancer Agents$251,630
ZIA · FY2017 · TR · contact PI
qHTS for Inhibitors of Inflammasome Signaling$121,984
ZIA · FY2016 · TR · contact PI
Phenotypic Toxicity Screening in FAK/Ewings Sarcoma$121,984
ZIA · FY2016 · TR · contact PI
Phenotypic Toxicity Screening in FAK/Ewings Sarcoma$57,000
ZIA · FY2015 · TR · contact PI
qHTS to Identify Inhibitors of the Glycine Cleavage System (GCS)$57,000
ZIA · FY2015 · TR · contact PI
Identification of Inverse Agonists of Glucagon-like Peptide 1 (GLP1)$57,000
ZIA · FY2015 · TR · contact PI
Identification of Agonists of Glucagon-like Peptide 1 (GLP1)$57,000
ZIA · FY2015 · TR · contact PI
qHTS to Identify compounds to bypass IL-2 anergy in mouse T-cells$57,000
ZIA · FY2015 · TR · contact PI
qHTS for Inhibitors of Vif-A3F Interactions$57,000
ZIA · FY2015 · TR · contact PI
qHTS for Inhibitors of Vif-A3G Interactions$57,000
ZIA · FY2015 · TR · contact PI
qHTS to Identify Activators of BRCA1 Expression$57,000
ZIA · FY2015 · TR · contact PI
Identification of Inhibitors of SMAD3-mediated TGFb Signaling$57,000
ZIA · FY2015 · TR · contact PI
qHTS for Inhibitors of Inflammasome Signaling$57,000
ZIA · FY2015 · TR · contact PI
Identification of Inhibitors of Pin1$57,000
ZIA · FY2015 · TR · contact PI
Matrix-based Screening of Ewing's Sarcoma & Osteosarcoma Lines$57,000
ZIA · FY2015 · TR · contact PI
Phenotypic Viability Screening using Thyroid Cancer Cells$19,000
ZIA · FY2015 · TR · contact PI
Development of Diverse Assay Formats to Study the Interaction of Glucokinase (GCK) with Glucokinase Regulatory Protein (GKRP) and Analysis of the Effect of Clinical Mutations on GKRP$19,000
ZIA · FY2015 · TR · contact PI
Phenotypic Viability Screening using Adrenal Cancer Cells$19,000
ZIA · FY2015 · TR · contact PI
qHTS to Identify Inhibitors of Progerin-expression and Progeria-implicated Phenotypes$19,000
ZIA · FY2015 · TR · contact PI